Evenity (Romosozumab) Dosing in Renal Impairment

Romosozumab (brand name Evenity, romosozumab-aqqg) is a humanized monoclonal antibody that inhibits sclerostin. It is FDA-approved for osteoporosis treatment in postmenopausal women at high fracture risk and in men at high fracture risk, given as a fixed monthly injection for 12 months. It is not a bisphosphonate and not a peptide hormone, and it should not be confused with denosumab, another monoclonal antibody used in osteoporosis that works by a different mechanism (RANKL inhibition).

The direct answer

Romosozumab (Evenity), a monoclonal antibody sclerostin inhibitor, requires no dose adjustment for any stage of chronic kidney disease, including patients on hemodialysis, according to its FDA prescribing information. This is because the drug's size and disposition mean it is cleared through the reticuloendothelial system and target-mediated pathways rather than renal filtration. The consequential clinical risk in advanced CKD is not altered drug exposure but hypocalcemia: the label warns that patients with severe renal impairment or on dialysis are at greater risk and that hypocalcemia must be corrected before treatment starts (FDA prescribing information).

How romosozumab works, and why that matters for kidney patients

Romosozumab binds and inhibits sclerostin, a protein made mainly by osteocytes that normally suppresses Wnt signaling in osteoblasts. Blocking sclerostin releases that brake on bone formation. Published trial data describe an early rise in bone formation markers (P1NP) alongside a fall in bone resorption markers (CTX) over the treatment course, a dual effect that is not replicated by bisphosphonates or denosumab alone. The exact magnitude of these marker changes and the associated bone mineral density gains reported in the FRAME and ARCH trials should be confirmed against the primary trial publications before being cited as precise figures; this draft intentionally avoids repeating specific percentages that could not be verified against a primary source during this rewrite.

The pharmacology matters directly for the renal question. Romosozumab is a large protein (roughly 149 kDa), well above the size threshold for glomerular filtration. Its clearance depends on the reticuloendothelial system and on target-mediated disposition (binding to and being cleared alongside sclerostin), not on kidney excretion. That is the mechanistic reason no dose adjustment is needed across the spectrum of renal function.

What the FDA label actually says about renal impairment

The Evenity label states that no dose modification is recommended for patients with renal impairment, including those on hemodialysis. The regimen remains 210 mg, given as two 105 mg subcutaneous injections at the same visit, once monthly for 12 consecutive months (FDA label).

This is a meaningfully different position from oral and intravenous bisphosphonates, several of which carry renal function cutoffs below which they are not recommended or are contraindicated. Denosumab, like romosozumab, does not require renal dose adjustment, but it carries its own hypocalcemia risk in CKD and, unlike romosozumab, must be continued indefinitely once started to avoid rebound bone loss. Practically, romosozumab and denosumab are the two bone-active agents most often discussed for patients with severe kidney disease and confirmed osteoporosis, as distinct from renal osteodystrophy.

The label's renal-impairment warning is the operative safety statement here: patients with severe renal impairment or on dialysis are at greater risk of hypocalcemia, and hypocalcemia must be corrected before the first dose, with calcium and vitamin D supplementation and monitoring during treatment. Readers and clinicians should pull the current label text directly rather than rely on a paraphrase for exact wording, since label language can be updated.

Should dose or schedule change based on eGFR? No, but monitoring intensity should

Population pharmacokinetic evaluations referenced in the FDA label indicate that renal function across mild, moderate, and severe impairment categories did not meaningfully change romosozumab exposure. Because the molecule is not renally cleared, this is consistent with its pharmacology. A specific study name and exact AUC/Cmax comparisons appear in some secondary summaries of this data; those specifics require verification against the primary regulatory submission or a peer-reviewed source before being repeated as fact.

What changes with declining eGFR is not the dose, but the metabolic environment the dose enters. Patients with CKD stages 4 and 5 commonly have disrupted calcium, phosphate, PTH, and vitamin D metabolism, with secondary hyperparathyroidism close to universal at eGFR below 30. Adding a potent bone-forming agent into that environment accelerates calcium uptake into new bone matrix, which can lower serum calcium abruptly. This is the clinical reason CKD patients need a different monitoring plan, not a different dose.

Hypocalcemia: the central clinical concern in advanced CKD

In patients with normal kidney function, symptomatic hypocalcemia from romosozumab appears to be uncommon based on the trial populations studied, though those pivotal trials excluded patients with eGFR below 30, so controlled data in advanced CKD are limited. Case reports and post-marketing safety reporting have described severe hypocalcemia in CKD patients receiving romosozumab, in some cases requiring intravenous calcium correction, and the FDA label reflects this by singling out severe renal impairment and dialysis as risk factors. The absolute frequency of these events in current pharmacovigilance data was not independently verified for this draft and should be checked against the FDA Adverse Event Reporting System or the current label before being cited as a rate.

Before the first injection in a CKD patient

• Confirm 25-hydroxyvitamin D is not deficient, and correct deficiency before starting.
• Confirm corrected serum calcium is within the normal range.
• Check intact PTH. Markedly elevated PTH can indicate adynamic bone disease or severe secondary hyperparathyroidism that should be addressed separately before romosozumab is considered.
• In dialysis patients, coordinate with the existing CKD-MBD regimen (active vitamin D analog, phosphate binders) rather than starting romosozumab in isolation.

During the 12-month course

A reasonable, cautious monitoring approach for patients with eGFR below 30 or on dialysis, reflecting site-level clinical judgment rather than an explicit FDA-mandated schedule, is:

• Check corrected serum calcium at baseline and again roughly 1 to 2 weeks after each of the first several injections.
• If calcium is stable, monitoring can reasonably move to a pre-injection check each month.
• Check phosphate and intact PTH periodically (for example, every three months) during the course.
• Recheck vitamin D status partway through the course to confirm supplementation is adequate.

Any symptomatic hypocalcemia (perioral tingling, carpopedal spasm, or QTc prolongation on ECG) warrants immediate evaluation and treatment, and the next dose should be held pending reassessment. This is a general safety principle, not a substitute for individualized dosing or emergency guidance from the treating clinician.

Osteoporosis or renal osteodystrophy? Why this distinction matters before prescribing

CKD-mineral and bone disorder (CKD-MBD) covers a spectrum that includes high-turnover disease from hyperparathyroidism, low-turnover (adynamic) bone disease, mixed uremic osteodystrophy, and osteomalacia. Romosozumab is approved for osteoporosis. It is not indicated for renal osteodystrophy, and the two conditions can overlap biochemically in a patient with advanced CKD.

KDIGO's CKD-MBD guideline framework recommends assessing fracture risk in patients across CKD stages 3a through 5D before starting osteoporosis therapy, and considering bone biopsy when the specific type of renal bone disease would change management. In practice, biopsy with tetracycline labeling is rarely performed, so clinicians typically lean on DXA results, fracture history, and PTH trends to decide whether standard osteoporosis, rather than adynamic bone disease or severe hyperparathyroidism, is the dominant process. This is a guideline recommendation and a matter of clinical judgment, not a fixed lab cutoff; a widely cited but debated PTH threshold (often discussed around 500 to 800 pg/mL) is sometimes used as a rough marker of "too high to proceed without further workup," but exact numbers should be confirmed against the current KDIGO document rather than treated as an approved cutoff.

What the pivotal trials show, and what they do not

The FRAME and ARCH trials established romosozumab's fracture-reduction efficacy compared with placebo and with alendronate, respectively, and are the basis for the drug's approval. Both trials excluded patients with an eGFR below 30 mL/min/1.73 m². Reported subgroup analyses by baseline renal function within the enrolled range (eGFR 30 to 59 versus 60 and above) are described in some secondary sources as showing consistent benefit, but the trials were not powered for a CKD-specific conclusion, and the exact effect sizes require confirmation against the primary trial publications before being restated as precise numbers.

What the trials do not establish is efficacy or safety in patients with eGFR below 30 or on dialysis. No randomized controlled trial specifically enrolled that population. Pharmacokinetic data support similar drug exposure regardless of renal function, but fracture-reduction benefit in the presence of CKD-MBD pathology has not been confirmed in a controlled trial. This is a real evidence gap, not a technicality, and it should shape how confidently a clinician extrapolates trial-level fracture benefit to a dialysis patient.

The cardiovascular boxed warning, in a CKD population

The FDA boxed warning states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death, and that it should not be used in patients with an MI or stroke in the preceding year (FDA label). This warning is especially relevant in CKD, where cardiovascular disease prevalence is already elevated independent of romosozumab.

Whether the cardiovascular signal observed in trials reflects a true drug effect, an imbalance in baseline risk between treatment arms, or an artifact of comparing against an active comparator with its own cardiovascular profile remains debated in the literature, and any specific relative-risk figures attributed to a particular meta-analysis should be checked against that publication before being quoted. The practical approach for CKD patients is a documented cardiovascular risk assessment before prescribing, confirmation of no recent MI or stroke, and an individualized discussion in dialysis patients with known coronary disease, weighing fracture benefit against an uncertain cardiovascular signal.

After the 12-month course: sequencing in CKD

Romosozumab's anabolic effect is time-limited, and bone density gains are not durable without a follow-on antiresorptive. In patients with normal renal function, the standard sequence is romosozumab for 12 months followed by a bisphosphonate or denosumab.

In CKD stages 4 and 5, bisphosphonates are generally avoided or contraindicated depending on the specific agent and eGFR threshold, which narrows the sequencing options. Denosumab does not require renal dose adjustment and is the option most often discussed after romosozumab in advanced CKD, though it carries its own hypocalcemia risk in this population and requires an indefinite dosing commitment, since stopping denosumab is associated with rebound bone loss and vertebral fracture risk. A reasonable approach discussed in clinical practice, subject to individualized decision-making:

• Transition to denosumab on its labeled schedule.
• Continue calcium, vitamin D, and (in dialysis patients) active vitamin D analog supplementation.
• Monitor serum calcium after each denosumab dose, following the same rationale as during romosozumab treatment.
• Do not stop denosumab without a clear follow-on plan; bisphosphonate bridging may become an option later if renal function improves, for example after a kidney transplant.

Kidney transplant recipients

Post-transplant osteoporosis is common, driven by glucocorticoid exposure, calcineurin inhibitor effects on bone, and pre-existing CKD-MBD carried into the transplant. Small case series have reported romosozumab use in kidney transplant recipients with bone density improvement and no reported graft dysfunction, but this is preliminary observational evidence, not trial evidence, and no randomized trial has evaluated romosozumab specifically in this population. Before considering it in a transplant recipient, clinicians typically want stable graft function (commonly framed as eGFR above 30) and an immunosuppressive regimen already optimized toward the lowest feasible glucocorticoid dose, with the same calcium monitoring described above.

Practical dosing summary

The 210 mg dose is given as two separate 105 mg/1.17 mL prefilled syringes, injected subcutaneously into the abdomen, thigh, or upper arm, both administered at the same visit with rotated injection sites each month. For CKD patients, the injection technique, volume, and monthly schedule do not change. What changes is the added pre-treatment laboratory workup, more frequent calcium monitoring, and documented cardiovascular risk assessment described above. Treatment is fixed at 12 monthly doses; the FDA label does not support extending beyond 12 months.

A decision framework: should this CKD patient start romosozumab?

This is not a dosing calculator, because romosozumab dosing does not change with renal function. It is a structured way to decide whether starting is appropriate and how tightly to monitor, built from the label warnings and guideline framework above. It is a starting point for discussion with the prescribing clinician, not a substitute for individualized medical judgment.

The recurring theme across every row is that eGFR changes the monitoring plan and the differential diagnosis workup, never the dose itself.

Evidence boundary: what is established, what is plausible, what is not established

Established, from the FDA label: no dose adjustment is needed for any stage of renal impairment, including dialysis, and hypocalcemia must be corrected before starting and monitored during treatment, with severe renal impairment and dialysis flagged as higher-risk groups.

Plausible but not established in controlled trials: that romosozumab produces similar fracture-reduction benefit in patients with eGFR below 30 or on dialysis as it does in the trial populations that excluded them. Pharmacokinetic similarity does not by itself prove efficacy or safety in a population with different underlying bone biology (CKD-MBD).

Not established: precise event rates for hypocalcemia or cardiovascular events specifically in advanced CKD populations, a validated PTH cutoff above which romosozumab should not be used, and long-term outcomes in kidney transplant recipients, where only small case series exist.

Sourcing note for reviewers

This draft intentionally removed several precise trial statistics (specific percentage reductions in fracture risk, exact marker changes, exact relative-risk figures for cardiovascular events, and a named pharmacokinetic study) that appeared in the prior version of this page, because the underlying identifiers could not be independently verified during this rewrite. The FDA label URL is a stable institutional source and is used for general labeling claims. Any restoration of specific trial numbers (ARCH, FRAME, cardiovascular meta-analyses, transplant case series) should be done only after confirming the correct primary citation, since a mismatched citation is worse than no citation.